SCHEMBL3076090

SCHEMBL3076090

C=CCCCCCCCCC(OS(=O)(=O)O)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.36
CYP2C19 P33261 1/20 0.36
MAPT P10636 3/20 0.33
ABCC4 O15439 1/20 0.33
SLC7A5 Q01650 5/20 0.33
ALDH1A1 P00352 4/20 0.33
USP2 O75604 2/20 0.33
HPGD P15428 2/20 0.33
CYP3A4 P08684 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SRC P12931 1/20 0.32
GSR P00390 1/20 0.31
HDAC2 Q92769 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087780 1.00 TDP1 (0.36) TDP1CYP2C19MAPTABCC4SLC7A5
SCHEMBL3069638 1.00 TDP1 (0.36) TDP1CYP2C19MAPTABCC4SLC7A5
SCHEMBL3074653 1.00 TDP1 (0.36) TDP1CYP2C19MAPTABCC4SLC7A5
SCHEMBL3089633 1.00 TDP1 (0.36) TDP1CYP2C19MAPTABCC4SLC7A5
SCHEMBL3094432 0.99 TDP1 (0.37) TDP1CYP2C19MAPTABCC4SLC7A5
SCHEMBL3083588 0.94 TDP1 (0.38) TDP1CYP2C19MAPTALDH1A1CYP3A4
SCHEMBL3088056 0.88 CYP2C19 (0.39) TDP1CYP2C19MAPTALDH1A1HPGD
SCHEMBL869575 0.81 NAAA (0.44) ALDH1A1SMN1; SMN2
SCHEMBL3091268 0.79 CYP2C19 (0.49) TDP1CYP2C19MAPTALDH1A1HPGD
SCHEMBL3092713 0.78 LPAR3 (0.43) CYP2C19MAPTABCC4SLC7A5ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US claimed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US claimed
US-20150132797-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING LIFE TECHNOLOGIES CORP (US) 2015-05-14 US disclosed
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents GENZYME CORPORATION (US) 2010-07-08 US disclosed
US-7678369-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2010-03-16 US disclosed
US-20080038773-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
US-20080038772-A1 COMPOSITION, METHOD AND KIT FOR REDUCING BACKGROUND STAINING INVITROGEN CORPORATION (US) 2008-02-14 US disclosed
EP-1189622-B1 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GENZYME CORP (US) 2007-07-25 EP disclosed
EP-1800686-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
EP-1800687-A2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2007-06-27 EP disclosed
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents GENZYME CORPORATION (US) 2006-02-09 US disclosed
US-6890523-B2 Anionic polymers as toxin binders and antibacterial agents GENZYME CORPORATION (US) 2005-05-10 US disclosed
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents GELTEX PHARMACEUTICALS, INC. 2003-07-24 US disclosed
US-6517827-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
US-6517826-B1 Polystyrene sulfonate polymer; Clostridium difficile GELTEX PHARMACEUTICALS, INC. 2003-02-11 US disclosed
EP-1189622-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS Geltex Pharmaceuticals, Inc. (US) 2002-03-27 EP disclosed
US-6290946-B1 ADMINISTERING TO THE ANIMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A POLYMER HAVING A PLURALITY OF PENDANT ACID FUNCTIONAL GROUPS WHICH ARE DIRECTLY ATTACHED TO THE POLYMER BACKBONE OR ATTACHED TO THE POLYMER BACKBONE BY A SPACER GROUP. GELTEX PHARMACEUTICALS, INC. 2001-09-18 US disclosed
WO-2000069428-A2 ANIONIC POLYMERS AS TOXIN BINDERS AND ANTIBACTERIAL AGENTS GELTEX PHARMACEUTICALS, INC. (US) 2000-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100172861-A1 Anionic Polymers as Toxin Binders and Antibacterial Agents MSN, ANTXR2, PNKP TDP1 2769/4885CYP2C19 4744/4885MAPT 2439/4885
US-20060029568-A1 Administering a polymer with pendant acid functional groups or a salt with a pharmaceutically acceptable cation; free of acid anhydride groups; antidiarrhea agents DDOST, DNPEP, IDUA TDP1 2887/4885CYP2C19 4413/4885MAPT 3504/4885
US-20030138397-A1 Anionic polymers as toxin binders and antibacterial agents MSN, ANTXR2, PNKP TDP1 2769/4885CYP2C19 4744/4885MAPT 2439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.